Medicover AB (publ)

OM:MCOV B Stock Report

Market Cap: SEK 34.2b

Medicover Valuation

Is MCOV B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MCOV B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: MCOV B (SEK225) is trading below our estimate of future cash flow value (SEK633.53)

Significantly Below Future Cash Flow Value: MCOV B is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MCOV B?

Key metric: As MCOV B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MCOV B. This is calculated by dividing MCOV B's market cap by their current earnings.
What is MCOV B's PE Ratio?
PE Ratio36.4x
Earnings€84.90m
Market Cap€3.09b

Price to Earnings Ratio vs Peers

How does MCOV B's PE Ratio compare to its peers?

The above table shows the PE ratio for MCOV B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.7x
ASKER Asker Healthcare Group
43.1x16.96%SEK 30.8b
ATT Attendo
17.9x8.16%SEK 15.7b
DEDI Dedicare
13.7xn/aSEK 526.9m
AMBEA Ambea
16x13.05%SEK 11.4b
MCOV B Medicover
36.4x24.23%SEK 34.2b

Price-To-Earnings vs Peers: MCOV B is expensive based on its Price-To-Earnings Ratio (36.4x) compared to the peer average (22.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does MCOV B's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MCOV B 36.4xIndustry Avg. 20.4xNo. of Companies12PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MCOV B is expensive based on its Price-To-Earnings Ratio (36.4x) compared to the European Healthcare industry average (20.4x).

Price to Earnings Ratio vs Fair Ratio

What is MCOV B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MCOV B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36.4x
Fair PE Ratio35.3x

Price-To-Earnings vs Fair Ratio: MCOV B is expensive based on its Price-To-Earnings Ratio (36.4x) compared to the estimated Fair Price-To-Earnings Ratio (35.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MCOV B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 225.00
SEK 253.64
+12.73%
11.66%SEK 300.22SEK 220.16n/a7
Jul ’27SEK 234.50
SEK 256.97
+9.58%
11.65%SEK 299.03SEK 220.29n/a6
Jun ’27SEK 205.50
SEK 256.97
+25.05%
11.65%SEK 299.03SEK 220.29n/a6
May ’27SEK 207.50
SEK 258.03
+24.35%
11.70%SEK 300.11SEK 221.09n/a6
Apr ’27SEK 193.40
SEK 263.24
+36.11%
12.32%SEK 310.13SEK 227.29n/a6
Mar ’27SEK 217.50
SEK 257.43
+18.36%
11.32%SEK 300.82SEK 220.47n/a6
Feb ’27SEK 202.50
SEK 260.10
+28.44%
12.04%SEK 310.17SEK 225.05n/a6
Jan ’27SEK 220.50
SEK 268.99
+21.99%
11.53%SEK 317.99SEK 230.73n/a6
Dec ’26SEK 235.00
SEK 268.99
+14.46%
11.53%SEK 317.99SEK 230.73n/a6
Nov ’26SEK 259.00
SEK 272.24
+5.11%
10.28%SEK 322.73SEK 238.24n/a6
Oct ’26SEK 255.50
SEK 272.40
+6.61%
10.25%SEK 319.94SEK 234.18n/a6
Sep ’26SEK 271.50
SEK 267.10
-1.62%
13.35%SEK 324.11SEK 219.05n/a6
Aug ’26SEK 269.00
SEK 264.69
-1.60%
13.92%SEK 325.07SEK 219.70n/a6
Jul ’26SEK 259.00
SEK 256.12
-1.11%
11.07%SEK 292.48SEK 219.90SEK 234.506
Jun ’26SEK 239.00
SEK 240.56
+0.65%
13.83%SEK 285.56SEK 207.80SEK 205.506
May ’26SEK 241.50
SEK 220.01
-8.90%
4.54%SEK 237.92SEK 208.53SEK 207.506
Apr ’26SEK 200.00
SEK 215.84
+7.92%
3.26%SEK 228.21SEK 206.85SEK 193.406
Mar ’26SEK 209.00
SEK 216.88
+3.77%
6.56%SEK 235.72SEK 188.81SEK 217.506
Feb ’26SEK 206.00
SEK 214.74
+4.24%
7.24%SEK 236.52SEK 189.93SEK 202.505
Jan ’26SEK 192.00
SEK 214.52
+11.73%
9.40%SEK 239.18SEK 178.92SEK 220.505
Dec ’25SEK 175.80
SEK 214.38
+21.94%
10.25%SEK 239.13SEK 178.89SEK 235.004
Nov ’25SEK 181.20
SEK 216.22
+19.32%
10.28%SEK 240.78SEK 180.11SEK 259.004
Oct ’25SEK 185.40
SEK 212.20
+14.46%
9.68%SEK 237.74SEK 180.47SEK 255.504
Sep ’25SEK 187.80
SEK 205.30
+9.32%
8.82%SEK 220.21SEK 179.80SEK 271.503
Aug ’25SEK 187.40
SEK 207.63
+10.80%
9.31%SEK 222.20SEK 180.31SEK 269.003
Jul ’25SEK 192.60
SEK 195.12
+1.31%
8.23%SEK 211.95SEK 173.48SEK 259.003
SEK 253.64
Fair Value
11.3% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/29 23:35
End of Day Share Price 2026/07/29 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicover AB (publ) is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
null nullABG Sundal Collier Sponsored
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB